• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by electroCore Inc.

    5/5/26 2:25:31 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    electroCore, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    28531P103

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    28531P103


    1Names of Reporting Persons

    Hilve Holdings Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CYPRUS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    517,522.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    517,522.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    517,522.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    28531P103


    1Names of Reporting Persons

    Mikhail Stiskin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    517,522.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    517,522.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    517,522.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    electroCore, Inc.
    (b)Address of issuer's principal executive offices:

    200 FORGE WAY, SUITE 205, ROCKAWAY, NEW JERSEY, 07866
    Item 2. 
    (a)Name of person filing:

    (i) Hilve Holdings Ltd and (ii) Mikhail Stiskin (collectively, the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    (i) For Hilve Holdings Ltd.: Spyrou Araouzou, 25, Beregaria 25, 5th Floor, Office 2, 3036, Limassol, Republic of Cyprus, (ii) For Mikhail Stiskin: Onisilou, 8A, Rita Court 1, Block B, Flat/Office 208, Agios Tychonas, 4532, Limassol, Republic of Cyprus.
    (c)Citizenship:

    (i) Hlive Holdings Ltd was established under the laws of the Republic of Cyprus, and (ii) Mikhail Stiskin is a citizen of Israel.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP Number(s):

    28531P103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Hilve Holdings Ltd directly holds 517,522 shares of Common Stock, par value $0.001 per share ("Common Stock"), of electroCore, Inc. (the "Issuer"). Mikhail Stiskin, as the sole shareholder of Hilve Holdings Ltd, may be deemed the beneficial owner of 517,522 shares of Common Stock held by Hilve Holdings.
    (b)Percent of class:

    Hilve Holdings Ltd may be deemed the beneficial owner of 6.4% of the outstanding shares of Common Stock of the Issuer. Mikhail Stiskin may be deemed the beneficial owner of 6.4% of the outstanding shares of Common Stock. Such percentages are based on 8,083,558 shares of Common Stock of the Issuer outstanding as of March 13, 2026, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on March 19, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    As of the date hereof, Hilve Holdings Ltd has the sole power to vote or to direct the vote of 517,522 shares of Common Stock of the Issuer. Mikhail Stiskin, as the sole shareholder of Hilve Holdings Ltd, has the sole power to vote or to direct the vote of 517,522 shares of Common Stock of the Issuer.

     (ii) Shared power to vote or to direct the vote:

    As of the date hereof, each of the Reporting Persons has shared power to vote or direct the vote of 0 shares of Common Stock of the Issuer.

     (iii) Sole power to dispose or to direct the disposition of:

    As of the date hereof, Hilve Holdings Ltd has the sole power to vote or to direct the vote of 517,522 shares of Common Stock of the Issuer. Mikhail Stiskin, as the sole shareholder of Hilve Holdings Ltd, has the sole power to vote or to direct the vote of 517,522 shares of Common Stock of the Issuer.

     (iv) Shared power to dispose or to direct the disposition of:

    As of the date hereof, each of the Reporting Persons has shared power to dispose or to direct the disposition of 0 shares of Common Stock of the Issuer.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Hilve Holdings Ltd
     
    Signature:Asya Andreeva
    Name/Title:Director
    Date:05/05/2026
     
    Mikhail Stiskin
     
    Signature:Mikhail Stiskin
    Name/Title:self
    Date:05/05/2026
    Get the next $ECOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Interim President Lev Joshua S. sold $60,003 worth of shares (6,667 units at $9.00), decreasing direct ownership by 7% to 84,889 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    5/29/26 4:05:12 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    5/26/26 8:52:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO and Interim President Lev Joshua S. sold $19,500 worth of shares (3,000 units at $6.50), decreasing direct ownership by 3% to 91,556 units (SEC Form 4) (tax liability)

    4 - electroCore, Inc. (0001560258) (Issuer)

    5/22/26 6:11:12 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    SEC Filings

    View All

    SEC Form 144 filed by electroCore Inc.

    144 - electroCore, Inc. (0001560258) (Subject)

    5/27/26 1:17:57 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by electroCore Inc.

    144 - electroCore, Inc. (0001560258) (Subject)

    5/14/26 3:48:21 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by electroCore Inc.

    10-Q - electroCore, Inc. (0001560258) (Filer)

    5/6/26 4:21:06 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    5/26/26 8:52:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    HC Wainwright & Co. reiterated coverage on electroCore with a new price target

    HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

    1/19/22 6:31:24 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on electroCore with a new price target

    Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

    7/27/21 7:13:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on electroCore with a new price target

    Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

    3/13/21 8:17:18 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub

    ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub being held at the Bellagio Resort & Casino in Las Vegas, NV. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one investor meetings throughout the conference. Planet MicroCap Las Vegas 2026 Powered by MicroCapClub Details: Dates: June 17 - 18, 2026Company Presentation: Wednesday, June 17 at 10:30 am PTLocation: Bellagio Resort & Casino, Las Vegas, NV Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpU

    6/2/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia

    ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, "Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial." The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy ("PT") for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group an

    5/13/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026

    ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA.   Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.   LD Micro Invitational XVI Conference Details: Date: Monday, May 18, 2026 Company Presentation: 10:30 am PT Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Webcast:   Click for Link For more information or to attend the conference, click here. About electroCore,

    5/8/26 8:00:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    View All

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Appoints James C. Theofilos to the Board of Directors

    ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. "I'm honored to have been appointed to the Board of Directors at electroCore," said Mr. Theofilos. "For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I've had the privilege of serving as the global finance lead for our healthcare and life sciences business — working alongside some of the worl

    8/5/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Join Russell Microcap® Index

    ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

    6/11/24 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Financials

    Live finance-specific insights

    View All

    electroCore Announces First Quarter 2026 Financial Results

    First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2026. The Company reported record quarterly revenue of $9.6 million, an increase of approximately 43% year-over-year, driven by continued growth in U.S. prescription sales in

    5/6/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Full Year 2025 Financial Results and Organizational Changes

    Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

    3/19/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

    SC 13D/A - electroCore, Inc. (0001560258) (Subject)

    6/7/24 4:33:08 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

    SC 13G/A - electroCore, Inc. (0001560258) (Subject)

    2/14/24 3:15:55 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by electroCore Inc.

    SC 13D - electroCore, Inc. (0001560258) (Subject)

    12/18/23 4:10:26 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care